Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HelicoMab-F
- Development stage
- Preclinical
- Lead developer
- BIO-FD&C
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
HelicoMab-F is an investigational monoclonal antibody therapy under development for the treatment of gastric cancer and gastritis. It is described as a novel antibody drug targeting conditions related to the stomach, including gastric inflammation and malignancy. The specific mechanism of action, molecular target, and detailed pharmacological profile have not been disclosed in publicly available sources as of June 2025. The drug appears to be part of a pipeline that includes other related antibodies (e.g., HelicoMab-GC), suggesting a focus on gastrointestinal disease[9].
- Brand names
- HelicoMab-F
- Other names
- HelicoMab-F
Beyond the preview
Go deeper on HelicoMab-F.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HelicoMab-F.